An in vitro study of two KRAS wild-type and two KRAS mutant CRC cell lines showed that ERCC1 was induced by oxaliplatin only in the KRAS wild-type cells, despite equivalent basal ERCC1 levels in all four cell lines. Here, KRAS is linked to colorectal carcinoma.